Phillip Musikanth
Internal Medicine · Los Angeles, CANPI 1760495741
Payments from drug & device makers
Across 544 payments — averaging $20.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$4K
- Gilead$2K
- EMD Serono, Inc.$800
- Johnson & Johnson$732
- AbbVie$493
- Napo Pharmaceuticals Inc$483
- plus $2K from 29 others
What the payments were for
- Speaking & faculty fees$1331%
- Food & beverage$11,06198%
- Education$611%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 195 | $3,967 |
| Gilead | 97 | $2,291 |
| EMD Serono, Inc. | 33 | $800 |
| Johnson & Johnson(2 entities) | 47 | $732 |
| AbbVie(2 entities) | 21 | $493 |
| Napo Pharmaceuticals Inc | 29 | $483 |
| Amgen | 16 | $384 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $273 |
| Merck | 12 | $237 |
| Theratechnologies Inc. | 7 | $217 |
| Antares Pharma, Inc. | 12 | $208 |
| Bausch Health US, LLC | 8 | $154 |
| Amarin Pharma, Inc. | 6 | $128 |
| GSK | 7 | $124 |
| Pfizer | 5 | $90 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $79 |
| Lilly USA, LLC | 3 | $66 |
| Nestle Healthcare Nutrition Inc. | 3 | $56 |
| Idorsia Pharmaceuticals US Inc | 3 | $55 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $50 |
| Sanofi Pasteur Inc. | 2 | $41 |
| Eisai Inc. | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| Janssen Products, LP | 1 | $30 |
| Novo Nordisk | 2 | $30 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Biohaven Pharmaceuticals, Inc. | 2 | $28 |
| Boston Scientific | 1 | $27 |
| Corcept Therapeutics | 1 | $20 |
| AstraZeneca | 1 | $19 |
| Dynavax Technologies Corporation | 1 | $16 |
| Acerus Pharmaceuticals Corporation | 1 | $16 |
| MDD US Operations, LLC | 1 | $14 |
| Vyera Pharmaceuticals, LLC | 1 | $14 |
| Endo Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CABENUVA$117
How this compares
$11,254 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SerostimSomatropin | 56 | $1,090,388 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 201 | $781,633 |
| JulucaDolutegravir/Rilpivirine | 163 | $563,109 |
| DescovyEmtricitabine/Tenofov Alafenam | 142 | $315,982 |
| TivicayDolutegravir Sodium | 116 | $315,011 |
| RukobiaFostemsavir Tromethamine | 23 | $265,167 |
| IsentressRaltegravir Potassium | 109 | $215,724 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 28 | $156,903 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 20 | $71,992 |
| DovatoDolutegravir Sodium/Lamivudine | 21 | $61,495 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 15 | $60,028 |
| Diclofenac Potassium | 15 | $59,466 |
| PrezcobixDarunavir/Cobicistat | 20 | $52,266 |
| Etravirine | 43 | $44,948 |
| FuzeonEnfuvirtide | 13 | $42,795 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyJuluca, Tivicay, Rukobia, Triumeq, Dovato | $3,967 | $1,276,774343 claims |
| GileadBiktarvy, Descovy, Genvoya, Vemlidy | $2,291 | $1,174,852371 claims |
| EMD Serono, Inc.Serostim | $800 | $1,090,38856 claims |
| MerckIsentress, Pifeltro, Januvia | $237 | $252,558139 claims |
| Janssen Products, LPSymtuza | $30 | $156,90328 claims |
| Johnson & JohnsonPrezcobix, Xarelto | $732 | $61,67538 claims |
| Novo NordiskOzempic | $30 | $37,17342 claims |
| PfizerEliquis | $90 | $10,89319 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $32 | $6,40912 claims |
| Eisai Inc.Dayvigo | $41 | $4,12913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Los Angeles
- William TownerLos Angeles$27.4M
- Herbert EradatLos Angeles$11.6M
- Deborah WongLos Angeles$10.7M
- Robin KelleyLos Angeles$5.8M
- David GuzmanLos Angeles$4.3M
- Siwen Hu-LieskovanLos Angeles$2.9M
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- Rahul AggarwalSan Francisco$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.